Patent Grant
12304980
The present disclosure generally relates to compositions that include a blend of polymerization inhibitors and methods of using the same to inhibit unwanted polymerization in vapor-space areas. More particularly, the present disclosure relates to compositions that include at least one compound having a hydroxylamine of stable nitroxide radical, a quinone and a phenylenediamine, useful for inhibiting polymerization of ethylenic unsaturated monomers.
Ethylenically unsaturated monomers are typically manufactured in a three-stage process consisting of (i) reaction, (ii) recovery, and (iii) purification. Distillation operations at elevated temperatures are often involved in the recovery and purification stages. The processes include fractional distillation of the monomers. In the top sections of the distillation columns, purified monomer vapor condenses into liquid pools prior to transfer into storage facilities. Some of the condensed monomer streams cascade down the column. In the vapor space areas of the distillation column, the liquid monomer pools are likely to generate spontaneous or peroxide-initiated free-radicals. Current polymer inhibitor technologies are confined to liquid streams in the bottom sections of the process columns. The inhibitors are typically non-volatile so that they are confined to the bottom section of the distillation column, and no inhibitor reaches highly reactive monomer pools in the vapor-space sections. With conventional inhibitors, the pooled monomers are not treated to abate unwanted polymerization. For this reason, reactive monomers undesirably polymerize through radical polymerization especially at elevated temperature or when in contact with rust on the surfaces of the process equipment such as distillation column trays.
In the presence of polymerization initiators such as organic peroxides, which are ubiquitous in recycled streams previously exposed to atmospheric oxygen, this polymerization is particularly acute. Conventional polymerization inhibitors, such as 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (HTEMPO) and 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl (OTEMPO) are generally effective. The premature polymerization of these monomers is generally controlled by directly dosing polymerization inhibitors into liquid hydrocarbon streams to reduce the premature polymerization of the monomers. However, these polymerization inhibitors (HTEMPO and OTEMPO) are not volatile. In the field, the process is accelerated when liquid monomer condenses on the trays, far above the bulk liquid that is treated with non-volatile polymerization inhibitors. The problem is acute if the trays have rust or when there are residual polymers in cracks and nooks. Equally important, preexisting polymers in equipment cracks, dead legs and stagnant pools of liquid monomer cause the rapid accumulation of foulant polymer due to the Norris-Trommsdorf effect. Due to accelerated polymerization, the growing polymer foulant causes mechanical damage and potential release of vast quantities of heat resulting in fires or explosions. The complete inhibition of tray corrosion or the complete removal of polymer from hard-to-reach locations in purification towers means that preventing unwanted polymerization in vapor spaces is difficult. It is in this regard that there is a pressing need for antipolymerants that are effective in the vapor-space sections of distillation columns.
A composition for inhibiting monomer polymerization is provided. The composition includes a first inhibitor compound comprising a hydroxylamine; a second inhibitor compound comprising a phenylenediamine; and a third inhibitor compound comprising a benzoquinone or naphthoquinone.
In some aspects, the first inhibitor compound is of formula (II):
wherein R2 is C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, C1-C22 cycloalkyl, aryl, —C1-C22 alkylene, —C(O)(C1-C22 alkyl), —C(O)(C1-C22 alkenyl), —C(O)(C1-C22 alkynyl), —C(O)(C1-C22 cycloalkyl), —C(O)(aryl), or —C(O)(C1-C22 alkylene), wherein the alkyl, alkylene, cycloalkyl, and aryl are optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl.
In some aspects, R2 is —C(O)(C1-C22 alkyl), —C(O)(C1-C22 alkenyl), —C(O)(C1-C22 alkynyl), —C(O)(C1-C22 cycloalkyl), —C(O)(aryl), or —C(O)(C1-C22 alkylene), wherein the alkyl, alkylene, cycloalkyl, and aryl are optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl.
In some aspects, the first inhibitor is selected from the group consisting of: 2,2,6,6-tetramethylpiperin-1,4-diol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-tridecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-icosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-henicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-ol; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-ol; 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-ol; and any combination thereof.
In some aspects, the first inhibitor is a compound of formula IIa:
wherein R4 is H, C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, C1-C22 cycloalkyl, aryl, —C1-C22 alkylene, —C(O)(C1-C22 alkyl), —C(O)(C1-C22 alkenyl), —C(O)(C1-C22 alkynyl), —C(O)(C1-C22 cycloalkyl), —C(O)(aryl), or —C(O)(C1-C22 alkylene), wherein the alkyl, alkylene, cycloalkyl, and aryl are optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl.
In some aspects, the first inhibitor is selected from the group consisting of: 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl acetate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl propanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl butyrate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl pentanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl hexanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl heptanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl octanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl nonanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl decanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylundecanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl stearate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl benzoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl palmitoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl behenoate, 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate, or any combination thereof.
In some aspects, the second inhibitor compound is a phenylenediamine of formula (IV) or formula (V):
wherein X1 and X2 are independently C1-C22 alkyl, or aryl, wherein the alkyl and aryl are optionally substituted with one or more C1-C22 alkyl or aryl.
In some aspects, the second inhibitor is selected from the group consisting of: 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-di-methyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-di-ethyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, N,N′-di-phenyl-1,4-phenylenediamine, and any combination thereof.
In some aspects, the third inhibitor compound is a benzoquinone of formula (VI) or formula (VII):
wherein X3, X4, X5, and X6 are independently H, C1-C22 alkyl, or aryl, wherein the alkyl and aryl are optionally substituted with one or more C1-C22 alkyl or aryl.
In some aspects, the third inhibitor compound is a naphthoquinone of formula (VII) or formula (VIII):
wherein X5 and X6 are independently H, C1-C22 alkyl, aryl, wherein the alkyl and aryl are optionally substituted with one or more C1-C22 alkyl or aryl.
In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 80% by weight, and the second inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight.
In some aspects, the composition further comprises an organic solvent.
In some aspects, the composition further comprises an ethylenic unsaturated monomer selected from the group consisting of vinyl acetate, acrylonitrile, an acrylate, a methacrylate, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid and any combination thereof.
A method of inhibiting polymerization of a monomer is provided. The method includes adding the composition described herein to the monomer.
In some aspects, the monomer is provided within a solution.
In some aspects, the solution further comprises one or more additional components selected from: an acid, an organic solvent, and water.
In some aspects, the monomer is an ethylenic unsaturated monomer.
In some aspects, the composition is added to the monomer such that a concentration of the first inhibitor compound is about 0.1 ppm to about 10,000 ppm.
In some aspects, the composition is added to the monomer such that a concentration of the second inhibitor compound is about 0.1 ppm to about 10,000 ppm.
In some aspects, the monomer is selected from the group consisting of vinyl acetate, acrylonitrile, an acrylate, a methacrylate, 1,3-butadiene, styrene, isoprene, acrylic acid, methacrylic acid and any combination thereof.
The foregoing has outlined rather broadly the features and technical advantages of the present disclosure in order that the detailed description that follows may be better understood. Additional features and advantages of the disclosure will be described hereinafter that form the subject of the claims of this application. It should be appreciated by those skilled in the art that the conception and the specific aspects disclosed may be readily utilized as a basis for modifying or designing other aspects for carrying out the same purposes of the present disclosure. It should also be realized by those skilled in the art that such equivalent aspects do not depart from the spirit and scope of the disclosure as set forth in the appended claims.
A detailed description of the invention is hereafter described with specific reference being made to the drawings.
Various aspects of the present disclosure are described below. The relationship and functioning of the various elements of the aspects may better be understood by reference to the following detailed description. However, aspects are not limited to those explicitly described herein and it should be understood that, in certain instances, details may have been omitted that are not necessary for an understanding of the aspects disclosed herein, such as—for example—conventional synthesis and/or formulation.
The present disclosure relates to compositions that include a blend of polymerization inhibitors and methods of using the same to inhibit the polymerization of ethylenic unsaturated monomers. Polymerization inhibitor compositions of the present disclosure include a hydroxylamine, a phenylenediamine, and a benzoquinone or naphthoquinone.
A “polymerization inhibitor,” in the presence of polymerizable monomers, inhibits the formation of a polymer from those monomers during the induction time. After the induction time has lapsed, the polymer's formation occurs at substantially the same rate that it would form at in the absence of the polymerization inhibitor.
Polymerization inhibitors and polymerization retarders can be considered generally as “antipolymerants” which are compounds that can inhibit or reduce the formation of polymers from one or more radically polymerizable compounds.
The term “fouling” refers to the formation of polymers, prepolymers, oligomer and/or other materials, which would become insoluble in and/or precipitate from a stream and deposit on equipment under the conditions of operation of the equipment. In turn, the inhibitor, retarder, and amine stabilizer components and compositions of the disclosure can be referred to as “antifouling” as they inhibit or reduce such formation.
Compositions of the Disclosure
The present disclosure relates to compositions for inhibiting monomer polymerization where the compositions include a first inhibitor compound includes a hydroxylamine, a second inhibitor compound comprising a phenylenediamine, and a third inhibitor compound comprising a benzoquinone or naphthoquinone. In some aspects, the compositions are for inhibiting monomer polymerization, where the monomer is an ethylenic unsaturated monomer. For example, the compositions of the disclosure are useful for inhibiting polymerization of ethylenic unsaturated monomers including, but not limited to, vinyl acetate, acrylonitrile, acrylates, methacrylates, 1,3-butadiene, styrene, isoprene, (meth)acrylic acid, and combinations thereof.
In some aspects, the first inhibitor compound is of formula (II):
where R2 is selected from H, C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, C1-C22 cycloalkyl, aryl, —C1-C22 alkylene, —C(O)(C1-C22 alkyl), —C(O)(C1-C22 alkenyl), —C(O)(C1-C22 alkynyl), —C(O)(C1-C22 cycloalkyl), —C(O)(aryl), and —C(O)(C1-C22 alkylene), wherein the alkyl, alkylene, cycloalkyl, and aryl are optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl.
The term “aryl” refers to monocyclic, bicyclic (fused), and tricyclic (fused or spiro) hydrocarbon ring systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring carbon atoms. The term “aryl” may be used interchangeably with the term “aryl ring.”
In certain aspects, R2 is —C(O)(C1-C22 alkyl), —C(O)(C1-C22 alkenyl), —C(O)(C1-C22 alkynyl), —C(O)(C1-C22 cycloalkyl), —C(O)(aryl), and —C(O)(C1-C22 alkylene), where the alkyl, alkylene, cycloalkyl, and aryl are optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl.
In some aspects, R2 is H. In some aspects, R2 is C1-C22 alkyl. In some aspects, R2 is C1-C22 alkenyl. In some aspects, R2 is C1-C22 alkynyl. In some aspects, R2 is C1-C22 cycloalkyl, where the cycloalkyl is optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl. In some aspects, R2 is aryl, where the aryl is optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl. In some aspects, R2 is —C1-C22 alkylene, where the alkylene is optionally substituted with aryl that is optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl. In some aspects, R2 is —C(O)(C1-C22 alkyl). In some aspects, R2 is —C(O)(C1-C12 alkyl). In some aspects, R2 is —C(O)(C1-C6 alkyl). In some aspects, R2 is —C(O)(methyl). In some aspects, R2 is —C(O)(ethyl). In some aspects, R2 is —C(O)(propyl). In some aspects, R2 is —C(O)(butyl). In some aspects, R2 is —C(O)(C1-C22 alkenyl). In some aspects, R2 is —C(O)(C1-C22 alkynyl). In some aspects, R2 is —C(O)(C1-C22 cycloalkyl), where the cycloalkyl is optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl. In some aspects, R2 is —C(O)(aryl), where the aryl is optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl. In some aspects, R2 is —C(O)(C1-C22 alkylene), where the alkylene is optionally substituted with aryl that is optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl.
In some aspects, the compound of formula (II) is 2,2,6,6-tetramethylpiperin-1,4-diol; 4-methoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-ethoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-butoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nonyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-undecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-dodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-tridecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-tetradecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-pentadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-hexadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-heptadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-octadecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-nodecyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-decyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-icosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-henicosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-docosyloxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-(phenoxy)-2,2,6,6-tetramethylpiperidin-1-ol; 4-(benzyloxy)-2,2,6,6-tetramethylpiperidin-1-ol; or 2,2,6,6-tetramethyl-4-(naphthalen-2-yloxy)piperidin-1-ol.
In certain aspects, the compositions of the disclosure include compounds of formula (I) and (II), respectively, where R1 and R2 are the same. For example, in some aspects, the compositions of the disclosure include compounds of formula (I) and (II), respectively, where R1 and R2 are each, independently, —C(O)(C1-C22 alkyl). In certain aspects, the compositions of the disclosure include first and second inhibitor compounds of formula (I) and (II), respectively, where R1 and R2 are different.
In some aspects, the second inhibitor compound having a hydroxylamine is selected from the group consisting of:
In some aspects, the second inhibitor compound having a hydroxylamine is:
4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol.
In some aspects, the second inhibitor compound having a hydroxylamine is:
4-propionoxy-2,2,6,6-tetramethylpiperidin-1-ol.
In some aspects, the second inhibitor compound having a hydroxylamine is:
4-butyroxy-2,2,6,6-tetramethylpiperidin-1-ol.
In some aspects, the second inhibitor compound having a hydroxylamine is:
4-valeroxy-2,2,6,6-tetramethylpiperidin-1-ol.
The presently disclosed compound of formula (II) having a hydroxylamine has benefits over the corresponding nitroxide (compound of formula (I)), such as the capability to provide additional polymerization inhibition, as will be more fully explained below. A general synthetic route to produce a hydroxylamine of a nitroxide is to reduce its corresponding nitroxide with a reducing reagent as follows:
A hydroxylamine of a nitroxide has the potential to provide additional polymerization inhibition as compared to the corresponding nitroxide when carbon-centered and oxygen-centered radical initiators are present. This is explained as follows:
The hydroxylamine of a nitroxide is an excellent hydrogen donor due to its weak NO—H bond in the compound, and thus it is an efficient antioxidant. As an antioxidant, the hydroxylamine of a nitroxide easily reacts with oxygen-centered radicals, such as peroxide radicals, while it's converted to its corresponding nitroxide. Nitroxides are generally known as the most effective inhibitors because of their superior inhibiting capabilities through scavenging carbon-centered free radicals at a nearly diffusion controlled rate. This rate is several orders of magnitude faster than phenolic compounds. However, their kinetic superiority is not always advantageous. For instance, it may lose its superiority when oxygen-centered radicals are present as the predominant free radicals. Another issue of concern with a nitroxide is its consumption through non-inhibition and unwanted reactions with process stream components or other inhibitor additives. As a result, high nitroxide inhibitor dosages are often required for a given inhibition efficacy, thereby making their use economically unattractive or even infeasible.
In essence, each hydroxylamine of a nitroxide is equivalent to one hydrogen donor plus one nitroxide antipolymerant when oxygen-centered radicals and carbon-centered radicals are both present, which is an attractive incentive offered by the hydroxylamines of nitroxides. That is, one hydroxylamine of a nitroxide is able to eliminate one oxygen-centered radical and one carbon-centered radical whereas a nitroxide is only capable to eliminate a carbon-centered radical.
In some aspects, the first inhibitor is a compound of formula IIa:
wherein R4 is H, C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, C1-C22 cycloalkyl, aryl, —C1-C22 alkylene, —C(O)(C1-C22 alkyl), —C(O)(C1-C22 alkenyl), —C(O)(C1-C22 alkynyl), —C(O)(C1-C22 cycloalkyl), —C(O)(aryl), or —C(O)(C1-C22 alkylene), wherein the alkyl, alkylene, cycloalkyl, and aryl are optionally substituted with one or more C1-C22 alkyl, C1-C22 alkenyl, C1-C22 alkynyl, or aryl.
In some aspects, the first inhibitor is a compound of formula III:
wherein R3 is —O· or —OH; and R4 is C1-C22 alkyl or aryl, wherein the alkyl and aryl are optionally substituted with one or more C1-C22 alkyl or aryl.
In some aspects, R3 is —O· In some aspects, R3 is —OH.
In some aspects with regard to formulae (IIa) and (III), R4 is C1-C22 alkyl that is optionally substituted with one or more C1-C22 alkyl or aryl. In some aspects with regard to formulae (IIa) and (III), R4 is C1-C5 alkyl that is optionally substituted with one or more C1-C22 alkyl or aryl. In some aspects with regard to formulae (IIa) and (III), R4 is C1-C4 alkyl that is optionally substituted with one or more C1-C22 alkyl or aryl. In some aspects with regard to formulae (IIa) and (III), R4 is C1-C10 alkyl that is optionally substituted with one or more C1-C22 alkyl or aryl. In some aspects with regard to formulae (IIa) and (III), R4 is C1—C alkyl that is optionally substituted with one or more C1-C22 alkyl or aryl. In some aspects, R4 is aryl that is optionally substituted with one or more C1-C22 alkyl or aryl. In some aspects, R4 is methyl. In some aspects, R4 is propyl. In some aspects, R4 is butyl. In some aspects, R4 is a C5 alkyl group. In some aspects, R4 is a C6 alkyl group. In some aspects, R4 is a C7 alkyl group. In some aspects, R4 is a C8 alkyl group. In some aspects, R9 is a C5 alkyl group. In some aspects, R4 is a C10 alkyl group. In some aspects, R4 is a C22 alkyl group. In some aspects, R4 is a C21 alkyl group. In some aspects, R4 is a C11 alkyl group. In some aspects, R4 is a benzyl group.
Examples of a compound of formulae (IIa) or (III) include, but are not limited to, 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl propanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl butyrate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl pentanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl hexanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl heptanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl octanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl nonanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl decanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl undecanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl dodecanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl 2-ethylhexanoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl stearate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl benzoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl palmitoate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl behenoate; or 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl 4-tert-butylbenzoate.
In some aspects, the compound of formulae (IIa) or (III) is 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl acetate; 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl propanoate; or 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl butyrate. In some aspects, the compound of formulae (IIa) or (III) is 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl acetate. In some aspects, the compound of formulae (IIa) or (III) is 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl propanoate. In some aspects, the compound of formulae (IIa) or (III) is 1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl butyrate.
In some aspects, the second inhibitor compound is a phenylenediamine of formula (IV) or formula (V):
wherein X1 and X2 are independently C1-C22 alkyl, or aryl, wherein the alkyl and aryl are optionally substituted with one or more C1-C22 alkyl or aryl.
In some aspects, the second inhibitor compound is a phenylenediamine of formula (IV). In some aspects, the second inhibitor compound is a phenylenediamine of formula (V).
Examples of phenylenediamines include, but are not limited to, 1,2-phenylenediamine, 1,4-phenylenediamine, N,N′-di-methyl-p-phenylenediamine, N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-di-ethyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, and N,N′-di-phenyl-1,4-phenylenediamine.
In some aspects, the phenylenediamine is N,N′-di-sec-butyl-1,4-phenylenediamine, N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine, N,N′-di-ethyl-1,4-phenylenediamine, N-tert-butyl-N′-phenyl-1,4-phenylenediamine, or N,N′-di-phenyl-1,4-phenylenediamine.
In some aspects, the phenylenediamine is N,N′-di-sec-butyl-1,4-phenylenediamine.
In some aspects, the phenylenediamine is N,N′-di-1,4-dimethylpentyl-1,4-phenylenediamine.
In some aspects, the phenylenediamine is N,N′-di-ethyl-1,4-phenylenediamine.
In some aspects, the phenylenediamine is N-tert-butyl-N′-phenyl-1,4-phenylenediamine.
In some aspects, the phenylenediamine is N,N′-di-phenyl-1,4-phenylenediamine.
In some aspects, the third inhibitor compound is a benzoquinone of formula (VI) or formula (VII):
wherein X3, X4, X5, and X6 are independently H, C1-C22 alkyl, or aryl, wherein the alkyl and aryl are optionally substituted with one or more C1-C22 alkyl or aryl.
In some aspects, the third inhibitor compound is a benzoquinone of formula (VI). In some aspects, the third inhibitor compound is a benzoquinone of formula (VII).
In some aspects, the third inhibitor compound is a naphthoquinone of formula (VII) or formula (VIII):
wherein X5 and X6 are independently H, C1-C22 alkyl, aryl, wherein the alkyl and aryl are optionally substituted with one or more C1-C22 alkyl or aryl.
In some aspects, X5 and X6 are independently H or C1-C22 alkyl.
In some aspects, X5 and X6 are independently H or C1-C15 alkyl.
In some aspects, X5 and X6 are independently H or C1-C10 alkyl.
In some aspects, X5 and X6 are independently H or C1-C5 alkyl.
In some aspects, the third inhibitor compound is a naphthoquinone of formula (VII). In some aspects, the third inhibitor compound is a naphthoquinone of formula (VIII).
In some aspects, X3, X4, X5, and X6 are independently H or C1-C22 alkyl. In some aspects, at least one of X3, X4, X5, and X6 is C1-C22 alkyl. In some aspects, X3, X4, and X5 are H and X6 is C1-C22 alkyl. In some aspects, X3, X4, and X5 are H and X6 is C1-C10 alkyl. In some aspects, X3, X4, and X5 are H and X6 is tert-butyl.
Examples of benzoquinones include, but are not limited to, 2-tert-butyl-1,4-benzoquinone, 2-tert-butyl-5-methylbenzoquinone, 2-sec-butyl-5-methylbenzoquinone, 2-n-butyl-5-methylbenzoquinone, 2-sec-butyl-5-methylbenzoquinone, 2-iso-propyl-5-methylbenzoquinone, 2,5-di-sec-butylbenzoquinone, 2,5-di-tert-butylbenzoquinone, 2,5-di-iso-popylbenzoquinone, 2,6-di-sec-butylbenzoquinone, 2,6-di-tert-butylbenzoquinone, 2,6-di-iso-popylbenzoquinone, 2,6-di-methylbenzoquinone, 2,5-di-methylbenzoquinone, 2,6-di-ethylbenzoquinone, 2,5-di-ethylbenzoquinone, 2,6-di-proylbenzoquinone, 2,5-di-propylbenzoquinone, 2,6-di-n-butylbenzoquinone, 2,5-di-n-buylbenzoquinone, 2,6-di-tert-butylbenzoquinone, 2,6-di-iso-propylbenzoquinone, 2-n-pentylbenzoquinone, 2,6-di-n-pentylbenzoquinone, 2,6-di-n-pentylbenzoquinone, 2-n-hexylbenzoquinone, 2,6-di-hexylbenzoquinone, 2,6-di-hexylbenzoquinone, 2-n-heptylbenzoquinone, 2,6-di-heptylbenzoquinone, 2,6-di-heptylbenzoquinone, 2-n-octylbenzoquinone, 2,6-di-octylbenzoquinone, 2,6-di-octylbenzoquinone, 2-n-nonylbenzoquinone, 2,6-di-nonylbenzoquinone, 2,6-di-nonylbenzoquinone, 2-n-decylbenzoquinone, 2,6-di-decylbenzoquinone, 2,6-di-decylbenzoquinone, 2-n-undecylbenzoquinone, 2,6-di-undecylbenzoquinone, 2,6-di-undecylbenzoquinone, 2-n-dodecylbenzoquinone, 2,6-di-dodecylbenzoquinone, and 2,6-di-dodecylbenzoquinone
In some aspects, the benzoquinone is 2-tert-butyl-1,4-benzoquinone.
Examples of naphthoquinones include, but are not limited to, 1,4-naphthoquinone, 1,2-naphthoquinone, 1-methyl-1,4-naphthoquinone, 1-ethyl-1,4-naphthoquinone, 1-n-propyl-1,4-naphthoquinone, 1-isopropyl-1,4-naphthoquinone, 1-n-butyl-1,4-naphthoquinone, 1-sec-butyl-1,4-naphthoquinone, 1-tert-butyl-1,4-naphthoquinone, 1-methyl-1,2-naphthoquinone, 1-ethyl-1,2-naphthoquinone, 1-n-propyl-1,2-naphthoquinone, 1-isopropyl-1,2-naphthoquinone, 1-n-butyl-1,2-naphthoquinone, 1-sec-butyl-1,2-naphthoquinone, and 1-tert-butyl-1,2-naphthoquinone
In some aspects, the composition consists essentially of a first inhibitor compound, a second inhibitor compound, and a third inhibitor compound. In other aspects, the composition consists of an organic solvent, a first inhibitor, a second inhibitor, and a third inhibitor compound. In some aspects, the composition does not include 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl.
In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 80% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 70% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 60% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 40% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 30% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 20% by weight. In some aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 10% by weight.
For example, in certain aspects, the first inhibitor compound is present in the composition at a concentration of about 0.01% by weight, about 0.1% by weight, about 1% by weight, about 5% by weight, about 10% by weight, about 15% by weight, about 20% by weight, about 25% by weight, about 30% by weight, about 35% by weight, about 40% by weight, about 45% by weight, about 50% by weight, about 55% by weight, about 60% by weight, about 65% by weight, about 70% by weight, about 75% by weight, or about 80% by weight.
In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 40% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 30% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 20% by weight. In some aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 10% by weight.
For example, in certain aspects, the second inhibitor compound is present in the composition at a concentration of about 0.01% by weight, about 0.1% by weight, about 1% by weight, about 5% by weight, about 10% by weight, about 15% by weight, about 20% by weight, about 25% by weight, about 30% by weight, about 35% by weight, about 40% by weight, about 45% by weight, or about 50% by weight.
In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 80% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 70% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 60% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 50% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 40% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 30% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 20% by weight. In some aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight to about 10% by weight.
For example, in certain aspects, the third inhibitor compound is present in the composition at a concentration of about 0.01% by weight, about 0.1% by weight, about 1% by weight, about 5% by weight, about 10% by weight, about 15% by weight, about 20% by weight, about 25% by weight, about 30% by weight, about 35% by weight, about 40% by weight, about 45% by weight, about 50% by weight, about 55% by weight, about 60% by weight, about 65% by weight, about 70% by weight, about 75% by weight, or about 80% by weight.
In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 100:1 to about 1:100. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 90:1 to about 1:90. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 80:1 to about 1:80. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 70:1 to about 1:70. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 60:1 to about 1:60. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 50:1 to about 1:50. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 40:1 to about 1:40. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 30:1 to about 1:30. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 20:1 to about 1:20. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 10:1 to about 1:10. In some aspects, a mole ratio of the first inhibitor compound to the second inhibitor compound is about 1:1.
In some aspects, the composition also includes one or more additional compounds selected from the group consisting of 2,2,6,6-tetramethylpiperidin-1-oxyl; 2,2,6,6-tetramethylpiperidin-1-ol; 4-hydroxyl-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-oxo-2,2,6,6-tetramethylpiperidin-1-ol; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol; 4-propionoxy-2,2,6,6-tetramethylpiperidin-1-oxyl; 4-propionoxy-2,2,6,6-tetramethylpiperidin-1-ol; and bis((2,2,6,6-tetramethylpiperidin-1-oxyl)-4-yl) oxalate. In some aspects, the composition also includes 2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-hydroxyl-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-oxo-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-acetoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes 4-propionoxy-2,2,6,6-tetramethylpiperidin-1-oxyl. In some aspects, the composition also includes 4-propionoxy-2,2,6,6-tetramethylpiperidin-1-ol. In some aspects, the composition also includes bis((2,2,6,6-tetramethylpiperidin-1-oxyl)-4-yl) oxalate.
The composition may optionally also include one or more organic solvents. One of ordinary skill in the art will appreciate that there are many organic solvents that are compatible with the compositions of the disclosure. For example, in some aspects, the one or more organic solvents are selected from vinyl acetate, dimethyl phthalate, dimethylformamide, toluene, xylene, highly aromatic naphtha, acetonitrile, ethyl acetate, acetone, dichloromethane, tetrahydrofuran, hexanes, dimethyl sulfoxide, N-methyl-2-pyrrolidone, and combinations thereof. In certain aspects, the composition also includes vinyl acetate. In certain aspects, the composition also includes dimethyl phthalate. In certain aspects, the composition also includes dimethylformamide. In certain aspects, the composition also includes toluene. In certain aspects, the composition also includes xylene. In certain aspects, the composition also includes highly aromatic naphtha. In certain aspects, the composition also includes acetonitrile.
In some aspects, the composition also includes one or more ethylenic unsaturated monomers. One of ordinary skill in the art will appreciate that there are many ethylenic unsaturated monomers that are compatible with the compositions of the disclosure. For example, in some aspects, the one or more ethylenic unsaturated monomers are selected from vinyl acetate, acrylonitrile, acrylate esters, methacrylate esters, 1,3-butadiene, styrene, isoprene, (meth)acrylic acid, and combinations thereof. In certain aspects, the composition also includes vinyl acetate. In certain aspects, the composition also includes acrylonitrile. In certain aspects, the composition also includes acrylates. In certain aspects, the composition also includes methacrylates. In certain aspects, the composition also includes 1,3-butadiene. In certain aspects, the composition also includes styrene. In certain aspects, the composition also includes isoprene. In certain aspects, the composition also includes acrylic acid and (meth)acrylic acid.
Methods of Using the Compositions of the Disclosure
The present disclosure also relates to methods of inhibiting polymerization of monomers that include adding a composition of the disclosure to the monomer. In some aspects, an effective amount of the composition of the disclosure is added to the monomer, where an effective amount is any amount sufficient to inhibit the polymerization of the monomer.
In some aspects, the monomer is an ethylenic unsaturated monomer. In some aspects the monomer is an ethylenic unsaturated monomer selected from vinyl acetate, acrylonitrile, acrylate esters, methacrylate esters, 1,3-butadiene, styrene, isoprene, (meth)acrylic acid, and combinations thereof are disclosed. In some aspects, the methods disclosed herein are useful in inhibiting the polymerization of vinyl acetate. In some aspects, the methods disclosed herein are useful in inhibiting the polymerization of acrylonitrile. In some aspects, the methods disclosed herein are useful in inhibiting the polymerization of acrylates. In some aspects, the methods disclosed herein are useful in inhibiting the polymerization of methacrylates. In some aspects, the methods disclosed herein are useful in inhibiting the polymerization of 1,3-butadiene. In some aspects, the methods disclosed herein are useful in inhibiting the polymerization of styrene. In some aspects, the methods disclosed herein are useful in inhibiting the polymerization of isoprene. In some aspects, the methods disclosed herein are useful in inhibiting the polymerization of (meth)acrylic acid.
The composition of the disclosure can be added manually or automatically to the fluid. The composition can also be added continuously and/or intermittently. Automatic addition may be accomplished through the use of chemical injection pumps. The chemical injection pumps may be programmed to add particular amounts of the polymerization inhibitor composition, or any components thereof, at certain time intervals to the fluid. In alternate aspects, the chemical injection pumps can be manually controlled to add particular amounts of the polymerization inhibitor composition, or any components thereof, to the fluid. Addition of the presently disclosed polymerization inhibitor compositions to the monomer will thereby inhibit polymerization of the monomer.
In some aspects, the monomer is provided as a neat liquid. In other aspects, the monomer is provided within a solution, hereafter referred to as “the monomer solution.”
In some aspects, the monomer solution also includes one or more additional components selected from an acid, an organic solvent, water, and combinations thereof. For example, in some aspects, the monomer solution includes one or more organic solvents selected from vinyl acetate, dimethyl phthalate, dimethylformamide, toluene, xylene, highly aromatic naphtha, acetonitrile, ethyl acetate, acetone, dichloromethane, tetrahydrofuran, hexanes, dimethyl sulfoxide, N-methyl-2-pyrrolidone, and combinations thereof.
In some aspects, the composition is added to the monomer such that a concentration of the first inhibitor compound is about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the first inhibitor compound is about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the first inhibitor compound is about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the first inhibitor compound is about 0.1 ppm to about 500 ppm.
In some aspects, the composition is added to the monomer such that a concentration of the second inhibitor compound is about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the second inhibitor compound is about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the second inhibitor compound is about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the second inhibitor compound is about 0.1 ppm to about 500 ppm.
In some aspects, the composition is added to the monomer such that a concentration of the third inhibitor compound is about 0.1 ppm to about 10,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the third inhibitor compound is about 0.1 ppm to about 5,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the third inhibitor compound is about 0.1 ppm to about 1,000 ppm. In some aspects, the composition is added to the monomer such that a concentration of the third inhibitor compound is about 0.1 ppm to about 500 ppm.
The methods of the disclosure are useful for inhibiting the premature polymerization of monomers during manufacturing process, particularly those that are performed under acidic conditions. For example, the methods of the disclosure are useful for preventing polymerization of acrylates, which may include, but are not limited to, acrylonitrile, acrylic acid, methyl methacrylic acid and its esters, and vinyl acetate.
The methods of the disclosure are also useful for preventing the premature polymerization of styrene during manufacturing and purification processes.
The methods of the disclosure are also useful in butadiene extraction processes. This utility stems from the balanced partition coefficients between polar organic phases and organic phases.
In some aspects, the compositions disclosed herein are used in distillative purification of olefins. For example, the composition can be added to the process stream before entering the distillation unit or the composition can be added to the process stream in the distillation unit.
The ability of compositions of the disclosure to inhibit the polymerization of polystyrene was assessed via the following protocol. Styrene was used as the reactive monomer for the polymerization kinetics studies and screening of the proposed antipolymerant products. To prevent polymerization during storage and transportation, styrene is stabilized with tert-butylcatechol (TBC). For each run of experiments, the stabilizer was removed, and the styrene thus freshly cleaned was used immediately. Styrene was used as the reactive monomer for the polymerization kinetics studies and screening of the proposed antipolymerant products. To prevent polymerization during storage and transportation, styrene is stabilized with TBC. For each run of experiments, the stabilizer was removed, and the styrene thus freshly cleaned was used immediately.
As a precaution, styrene that was cleaned and stored overnight, even under sub-zero refrigeration conditions, had to be discarded, since there was notable polymerization under storage. Alumina was used to remove the TBC using a chromatography column. The alumina column was prepared on the day of the scheduled set of experiments.
Into a 500 mL round bottom flask, about 300 mL of neat styrene treated with about 400 ppm of N,N-di-sec-butylphenylenediamine, the prototype PDA, were charged. A thermocouple was inserted directly into the reaction solution and the reaction temperature of the solution set for 115° C. To prevent the loss of the reaction solution due to evaporation, the flask was armed with a reflux equipment before being placed on a heating block. Through another port, a stream of nitrogen was flowed through the reaction solution while under vigorous stirring during the course of the kinetics study. The moment in time when the solution temperature reached 115° C. was designated as the beginning of the study, or time zero. A sample of the reaction solution was taken from the reactor after which the solution was immediately diluted with toluene. The concentration of polystyrene in the diluted solution was analyze using a proprietary procedure. From that point in time, a sample was collected every 20 minutes and the reaction solution similarly diluted and analyzed for the concentration of polystyrene.
The polymerization reactor was charged with 300 mL of styrene freshly cleaned and treated with 400 ppm of 4-Acetoxy TEMPOH. The reaction kinetics study was conducted as illustrated in Example 1.
Using the procedure in the above examples, the antipolymerant performance of 400 ppm of 2-tert-butylbenzoquinone was carried out.
A freshly prepared solution of styrene, 300 mL, was treated with 52 ppm of TBBQ, 174 ppm of PDA and 174 ppm of 4-Acetoxy TEMPOH. The solution was transferred into polymerization reactor followed by the kinetics study using the procedure in the foregoing examples.
The samples tested and the results of the assay are shown in
All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While this invention may be embodied in many different forms, there are described in detail herein specific preferred aspects of the invention. The present disclosure is an exemplification of the principles of the invention and is not intended to limit the invention to the particular aspects illustrated. In addition, unless expressly stated to the contrary, use of the term “a” is intended to include “at least one” or “one or more.” For example, “a compound” is intended to include “at least one compound” or “one or more compounds.”
Any ranges given either in absolute terms or in approximate terms are intended to encompass both, and any definitions used herein are intended to be clarifying and not limiting. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Moreover, all ranges disclosed herein are to be understood to encompass any and all subranges (including all fractional and whole values) subsumed therein.
Any composition disclosed herein may comprise, consist of, or consist essentially of any element, component and/or ingredient disclosed herein or any combination of two or more of the elements, components or ingredients disclosed herein.
Any method disclosed herein may comprise, consist of, or consist essentially of any method step disclosed herein or any combination of two or more of the method steps disclosed herein.
The transitional phrase “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, un-recited elements, components, ingredients and/or method steps.
The transitional phrase “consisting of” excludes any element, component, ingredient, and/or method step not specified in the claim.
The transitional phrase “consisting essentially of” limits the scope of a claim to the specified elements, components, ingredients and/or steps, as well as those that do not materially affect the basic and novel characteristic(s) of the claimed invention.
As used herein, the term “about” refers to the cited value being within the errors arising from the standard deviation found in their respective testing measurements, and if those errors cannot be determined, then “about” may refer to, for example, within 5% of the cited value.
Furthermore, the invention encompasses any and all possible combinations of some or all of the various aspects described herein. It should also be understood that various changes and modifications to the presently preferred aspects described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2344346 | Harry | Mar 1944 | A |
| 2642410 | Hoppens | Jun 1953 | A |
| 3445312 | Rider | May 1969 | A |
| 3632564 | Albert et al. | Jan 1972 | A |
| 3697470 | Haines et al. | Oct 1972 | A |
| 3816077 | Rosen et al. | Jun 1974 | A |
| 4079123 | Fuller et al. | Mar 1978 | A |
| 4216195 | Jaszka et al. | Aug 1980 | A |
| 4393035 | Fredette | Jul 1983 | A |
| 4735744 | Tsujimoto et al. | Apr 1988 | A |
| 4912247 | Roling | Mar 1990 | A |
| 5221764 | Roling | Jun 1993 | A |
| 5254760 | Winter et al. | Oct 1993 | A |
| 5258138 | Gatechair et al. | Nov 1993 | A |
| 5272231 | Campbell et al. | Dec 1993 | A |
| 5296567 | Baumann et al. | Mar 1994 | A |
| 5322960 | Sakamoto et al. | Jun 1994 | A |
| 5324497 | Westerlund | Jun 1994 | A |
| 5374697 | Muller | Dec 1994 | A |
| 5396004 | Arhancet et al. | Mar 1995 | A |
| 5710329 | Clever | Jan 1998 | A |
| 5728872 | Riemenschneider | Mar 1998 | A |
| 5856562 | Mine et al. | Jan 1999 | A |
| 5877344 | Gande et al. | Mar 1999 | A |
| 5888356 | Keil et al. | Mar 1999 | A |
| 5910232 | Hyde et al. | Jun 1999 | A |
| 5955643 | Lewis | Sep 1999 | A |
| 6051135 | Lee et al. | Apr 2000 | A |
| 6210536 | Grossi et al. | Apr 2001 | B1 |
| 6287483 | DeMassa et al. | Sep 2001 | B1 |
| 6300513 | Sakamoto et al. | Oct 2001 | B2 |
| 6300533 | Benage et al. | Oct 2001 | B1 |
| 6337426 | Winter | Jan 2002 | B1 |
| 6342647 | Roof et al. | Jan 2002 | B1 |
| 6344560 | Geelan et al. | Feb 2002 | B1 |
| 6348598 | Doi et al. | Feb 2002 | B1 |
| 6352619 | Fauconet et al. | Mar 2002 | B1 |
| 6403850 | Benage et al. | Jun 2002 | B1 |
| 6409887 | Pryce et al. | Jun 2002 | B1 |
| 6518374 | Aichinger et al. | Feb 2003 | B1 |
| 6518452 | Aichinger et al. | Feb 2003 | B1 |
| 6608226 | Reid et al. | Aug 2003 | B1 |
| 6642337 | Misiak et al. | Nov 2003 | B1 |
| 6660181 | Benage et al. | Dec 2003 | B2 |
| 6770219 | Tong | Aug 2004 | B2 |
| 6790427 | Charles et al. | Sep 2004 | B2 |
| 6806385 | Hammon et al. | Oct 2004 | B1 |
| 6864313 | Wunderlich et al. | Mar 2005 | B2 |
| 6956130 | Riondel et al. | Oct 2005 | B2 |
| 7005087 | Tong | Feb 2006 | B2 |
| 7022220 | Benage et al. | Apr 2006 | B2 |
| 7041711 | Kunita | May 2006 | B2 |
| 7056642 | Kano et al. | Jun 2006 | B2 |
| 7119224 | Schroeder et al. | Oct 2006 | B2 |
| 7261821 | Beardwood | Aug 2007 | B2 |
| 7368594 | Yurugi et al. | May 2008 | B2 |
| 7414162 | Link et al. | Aug 2008 | B2 |
| 7420013 | Riegel et al. | Sep 2008 | B2 |
| 7504074 | Martens et al. | Mar 2009 | B2 |
| 7553896 | Ma et al. | Jun 2009 | B2 |
| 7621821 | Tsai et al. | Nov 2009 | B2 |
| 7682592 | Charles et al. | Mar 2010 | B2 |
| 7799198 | Nanjundiah et al. | Sep 2010 | B2 |
| 8691994 | Tong | Apr 2014 | B2 |
| 8907121 | Johnson et al. | Dec 2014 | B2 |
| 9133288 | Loyns et al. | Sep 2015 | B2 |
| 9399622 | Tong | Jul 2016 | B2 |
| 9534065 | Nakaya et al. | Jan 2017 | B2 |
| 9561997 | Dafinger et al. | Feb 2017 | B2 |
| 9573874 | Fruchey et al. | Feb 2017 | B2 |
| 9611336 | Mo et al. | Apr 2017 | B2 |
| 9656891 | Martin | May 2017 | B2 |
| 9725649 | Subramaniyam | Aug 2017 | B2 |
| 9783480 | Aizawa et al. | Oct 2017 | B2 |
| 9884795 | Mo et al. | Feb 2018 | B2 |
| 9884951 | Tong | Feb 2018 | B2 |
| 9914701 | Masere et al. | Mar 2018 | B2 |
| 9932291 | Mendoza et al. | Apr 2018 | B2 |
| 9957209 | Masere et al. | May 2018 | B2 |
| 10112888 | Tong | Oct 2018 | B2 |
| 10221255 | Marguerre et al. | Mar 2019 | B2 |
| 10308585 | Tong | Jun 2019 | B2 |
| 10532320 | Boam et al. | Jan 2020 | B2 |
| 10640449 | Atkins et al. | May 2020 | B2 |
| 10696618 | Tong | Jun 2020 | B2 |
| 10745345 | Khanlari et al. | Aug 2020 | B2 |
| 10781157 | Cabon et al. | Sep 2020 | B2 |
| 10869444 | Masere et al. | Dec 2020 | B2 |
| 11104626 | Masere et al. | Aug 2021 | B2 |
| 11174439 | Vachon et al. | Nov 2021 | B2 |
| 11180578 | Masere et al. | Nov 2021 | B2 |
| 20010005755 | Sakamoto et al. | Jun 2001 | A1 |
| 20010009929 | Blankenship et al. | Jul 2001 | A1 |
| 20040031674 | Schroder | Feb 2004 | A1 |
| 20040175322 | Woodruff et al. | Sep 2004 | A1 |
| 20040236143 | Martan et al. | Nov 2004 | A1 |
| 20050010065 | Wartini et al. | Jan 2005 | A1 |
| 20050113626 | Benage | May 2005 | A1 |
| 20050139807 | Tong | Jun 2005 | A1 |
| 20060051285 | Hawker et al. | Mar 2006 | A1 |
| 20060096930 | Beardwood | May 2006 | A1 |
| 20060120946 | Simic et al. | Jun 2006 | A1 |
| 20060287548 | Hoefer et al. | Dec 2006 | A1 |
| 20070116637 | Woodruff et al. | May 2007 | A1 |
| 20070152187 | Truchlaeft | Jul 2007 | A1 |
| 20070167650 | Ishikawa et al. | Jul 2007 | A1 |
| 20080021241 | Carlson, Jr. et al. | Jan 2008 | A1 |
| 20090203938 | Croizy et al. | Aug 2009 | A1 |
| 20100168434 | Loyns et al. | Jul 2010 | A1 |
| 20100219371 | Paul | Sep 2010 | A1 |
| 20110015460 | Ding et al. | Jan 2011 | A1 |
| 20110160484 | Fruchey et al. | Jun 2011 | A1 |
| 20110290635 | Kar et al. | Dec 2011 | A1 |
| 20120203020 | Tong | Aug 2012 | A1 |
| 20120244063 | Pohjanvesi | Sep 2012 | A1 |
| 20130178652 | Fruchey et al. | Jul 2013 | A1 |
| 20130209349 | Vilhelmsson et al. | Aug 2013 | A1 |
| 20140097095 | Moser | Apr 2014 | A1 |
| 20140228604 | Colorado, Jr. et al. | Aug 2014 | A1 |
| 20140302176 | Grund et al. | Oct 2014 | A1 |
| 20150152053 | Tong | Jun 2015 | A1 |
| 20160083323 | Fruchey et al. | Mar 2016 | A1 |
| 20160102189 | Tong | Apr 2016 | A1 |
| 20160122643 | Fruchey et al. | May 2016 | A1 |
| 20180044180 | Burke et al. | Feb 2018 | A1 |
| 20180057740 | Cavezzan et al. | Mar 2018 | A1 |
| 20180264431 | Leeton et al. | Sep 2018 | A1 |
| 20180265447 | Linemann et al. | Sep 2018 | A1 |
| 20180273381 | Xiong et al. | Sep 2018 | A1 |
| 20180361319 | Boam et al. | Dec 2018 | A1 |
| 20190023641 | Chretien et al. | Jan 2019 | A1 |
| 20190185769 | Cuoq et al. | Jun 2019 | A1 |
| 20200017610 | Masere | Jan 2020 | A1 |
| 20200102408 | Masere | Apr 2020 | A1 |
| 20200277249 | Dafinger et al. | Sep 2020 | A1 |
| 20200283597 | Pelati | Sep 2020 | A1 |
| 20200339880 | Masere et al. | Oct 2020 | A1 |
| 20210108141 | Masere | Apr 2021 | A1 |
| 20210380523 | Bellini et al. | Dec 2021 | A1 |
| 20230312770 | Masere et al. | Oct 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 101304944 | Nov 2008 | CN |
| 102249842 | Nov 2011 | CN |
| 103073375 | May 2013 | CN |
| 105482851 | Apr 2016 | CN |
| 106103340 | Nov 2016 | CN |
| 106554244 | Apr 2017 | CN |
| 107987888 | May 2018 | CN |
| 108191640 | Jun 2018 | CN |
| 106512879 | Apr 2019 | CN |
| 106588647 | Apr 2020 | CN |
| 112028770 | Dec 2020 | CN |
| 113024447 | Jun 2021 | CN |
| 113457571 | Oct 2021 | CN |
| 294776 | Mar 2005 | CZ |
| 0325059 | Jul 1989 | EP |
| 0697386 | Feb 1996 | EP |
| 0569502 | Apr 1996 | EP |
| 0791573 | Aug 1997 | EP |
| 0620206 | May 2000 | EP |
| 1077206 | Feb 2001 | EP |
| 0845448 | Jan 2002 | EP |
| 1694715 | Oct 2007 | EP |
| 1248757 | Nov 2007 | EP |
| 2017293 | Jan 2009 | EP |
| 2257519 | Aug 2011 | EP |
| 2066613 | Jun 2012 | EP |
| 2903961 | Nov 2016 | EP |
| 2670800 | Jan 2018 | EP |
| 2504308 | May 2021 | EP |
| 590680 | Jul 1947 | GB |
| 688206 | Mar 1953 | GB |
| 2093464 | Sep 1982 | GB |
| H1143449 | Feb 1999 | JP |
| 2000063371 | Feb 2000 | JP |
| 2000072718 | Mar 2000 | JP |
| 2001069429 | Mar 2001 | JP |
| 2001163831 | Jun 2001 | JP |
| 3187345 | Jul 2001 | JP |
| 3197947 | Aug 2001 | JP |
| 3227204 | Nov 2001 | JP |
| 3235980 | Dec 2001 | JP |
| 3312639 | Aug 2002 | JP |
| 3529613 | May 2004 | JP |
| 2006199736 | Aug 2006 | JP |
| 2006282541 | Oct 2006 | JP |
| 4225707 | Feb 2009 | JP |
| 4270821 | Jun 2009 | JP |
| 4520092 | Aug 2010 | JP |
| 4548821 | Sep 2010 | JP |
| 4548822 | Sep 2010 | JP |
| 4582641 | Nov 2010 | JP |
| 5191702 | May 2013 | JP |
| 5334390 | Nov 2013 | JP |
| 6032463 | Nov 2016 | JP |
| 6158044 | Jul 2017 | JP |
| 6705120 | Jun 2020 | JP |
| 2020200465 | Dec 2020 | JP |
| 957153 | Sep 1982 | SU |
| 1999007664 | Feb 1999 | WO |
| 1999055797 | Nov 1999 | WO |
| 2000031005 | Jun 2000 | WO |
| 2000037412 | Jun 2000 | WO |
| 2000064947 | Nov 2000 | WO |
| 2001040404 | Jun 2001 | WO |
| 2001047844 | Jul 2001 | WO |
| 2002051784 | Jul 2002 | WO |
| 2002094884 | Nov 2002 | WO |
| 2007063031 | Jun 2007 | WO |
| 2010094982 | Aug 2010 | WO |
| 2015140549 | Sep 2015 | WO |
| 2017041204 | Mar 2017 | WO |
| 2017081611 | May 2017 | WO |
| 2017091599 | Jun 2017 | WO |
| 2017187150 | Nov 2017 | WO |
| 2018164226 | Sep 2018 | WO |
| 2018221314 | Dec 2018 | WO |
| 2019142887 | Jul 2019 | WO |
| 2020038496 | Feb 2020 | WO |
| 2020183105 | Sep 2020 | WO |
| 2021022550 | Feb 2021 | WO |
| Entry |
|---|
| Georgieff, K. K. (1965). Relative inhibitory effect of various compounds on the rate of polymerization of methyl methacrylate. Journal of Applied Polymer Science, 9(6), 2009-2018. doi:10.1002/app.1965.070090602. |
| Li, R., & Schork, F. J. (2006). Modeling of the Inhibition Mechanism of Acrylic Acid Polymerization. Industrial & Engineering Chemistry Research, 45(9), 3001-3008. doi:10.1021/ie0512439. |
| Ma, Yun (2012) Chapter 3: Mechanistic Investigation of Nitroxide-based Polymerization Inhibitors. PhD thesis, University of York. |
| Niesbach, A., Daniels, J., Schröter, B., Lutze, P., & Górak, A. (2013). The inhibition of acrylic acid and acrylate ester polymerisation in a heterogeneously catalysed pilot-scale reactive distillation column. Chemical Engineering Science, 88, 95-107. doi:10.1016/j.ces.2012.10.029. |
| Okutsu, R., Ando, S., & Ueda, M. (2008). Sulfur-Containing Poly(meth)acrylates with High Refractive Indices and High Abbe's Numbers. Chemistry of Materials, 20(12), 4017-4023. doi:10.1021/cm800432p. |
| International Search Report and Written Opinion, PCT/IB2023/060631, dated Feb. 14, 2024, 11 pages. |
| International Search Report and Written Opinion, PCT/US2023/069730, dated Oct. 23, 2023, 12 pages. |
| International Search Report and Written Opinion, PCT/US2023/069702, dated Oct. 18, 2023, 16 pages. |
| Appelt, M. and Schmidt-Naake, G. “Stable Free-Radical Copolymerization of Styrene with Acrylates Using OH-TEMPO,” Macromolecular Chemistry and Physics, 2004, vol. 205(6), pp. 637-644. |
| Bragd, P.L., Besemer, A.C., van Bekkum, H. “TEMPO-derivatives as catalysts in the oxidation of primary alcohol groups in carbohydrates,” Journal of Molecular Catalysis A: Chemical, 2001, vol. 170(1-2), pp. 35-42. |
| Brinkmann-Rengel, S., N. Niessner. “Controlled Radical Copolymerization of Styrene and Acrylonitrile,” American Cancer Society Symposium Series, chapter 28, vol. 768, Aug. 15, 2000, https://pubs.acs.org/doi/abs/10.1021/bk-2000-0768.ch02. |
| Edeleva, M.V., Marque, S.R., Bagryanskaya, E.G. “Imidazoline and imidazolidine nitroxides as controlling agents in nitroxide-mediated pseudoliving radical polymerization,” Russian Chemical Reviews, Apr. 2018, vol. 87(4), pp. 328-349. |
| Edwards, B. A. “Comparing reducing agents in a pilot scale CIO2 generator: does hydrogen peroxide measure up?,” Pulp & Paper Canada, 1996, vol. 97(5), pp. 34-37. |
| Georgieff, K.K. “Relative Inhibitory Effect of Various Compounds on the Rate of Polymerization of Methyl Methacrylate,” Journal of Applied Polymer Science, 1965, vol. 9(6), pp. 2009-2018. |
| Goldfein, M.D., Gladyshev, G.P. “Kinetics and Mechanism of the Inhibited Polymerisation of Vinyl Monomers,” Russian Chemical Reviews, 1988, vol. 57(11), p. 1083-1097. |
| Ichihara, K., Kawamura, I., Sakakibara, K. et al. “Inhibitory regulation mechanism of naphthoquinone and its derivatives in radical polymerization,” Journal of Physical Organic Chemistry, 2019, vol. 32(6), pp. 1-11. |
| Kuznetsova, Y.L., Mozaleva, P.G., Vavilova, A.S., et al. “Polymerization of methyl methacrylate in the presence of 2,5-di-tert-butyl-p-benzoquinone,” Russian Chemical Bulletin, Apr. 2020, vol. 69(4), pp. 763-767. |
| Ludin, D.V., Kuznetsova, Y.L., Zamyshlyaeva, O.G., Zaitsev, S.D. “Controlled Radical Copolymerization of Styrene and tert-Butyl Acrylate in the Presence of Tri-n-butylborane-p-Quinone Catalytic System,” Polymer Science, Series B, 2017, vol. 59(1), pp. 7-15. |
| Naz, A., Sattar, R., Siddiq, M. “Polymer membranes for biofouling mitigation: a review,” Polymer-Plastics Technology and Materials, 2019, vol. 58(17), pp. 1829-1854. |
| Pavlovskay, M.V., Smirnova, N.N., Markin, et al. “Synthesis of Block Copolymers from Polyvinyl Chloride Prepared in the Presence of Nitroxyl Radicals of the Imidazoline Series,” Russian Journal of Applied Chemistry, 2014, vol. 87(3), pp. 324-330. |
| Rodriquez, B., Oztruk, D. et al. “Antibiofouling thin-film composite membranes (TFC) by in situ formation of Cu-(m-phenylenediamine) oligomer complex,” Journal of Materials Science, Jan. 23, 2018, vol. 53, pp. 6325-6338. |
| Shushunova, N.Y., Arsenyev, M.V., Glukhova, T.A., et al. “Polymerization of Butyl Acrylate and Butyl Methacrylate in the Presence of o-Quinone Methacrylate,” Polymer Science Series B, 2015, vol. 57(3), pp. 207-216. |
| Wang, Y., Meng X., Wu H., et al. “Improving permeability and anti-fouling performance in reverse osmosis application of polyamide thin film nanocomposite membrane modified with functionalized carbon nanospheres,” Separation and Purification Technology, 2021, vol. 270, pp. 1-11. |
| Weng, S. and J. Zhang. “N-Oxyl-Radical-Catalyzed Intermolecular Aminooxygenation of Styrenes and Inter/intramolecular Aminoalkoxylation of Homoallylic Alcohols,” ChemCatChem, 2016, vol. 8(24), pp. 3720-3724. |
| Yin, W., Chu, C., Lu, Q. et al. “Iron Chloride/4-Acetamido-TEMPO/Sodium Nitrite-Catalyzed Aerobic Oxidation of Primary Alcohols to the Aldehydes,” Advanced Synthesis & Catalysis, 2010, vol. 352, pp. 113-118. |
| International Search Report and Written Opinion, PCT/US2020/026210, dated Jun. 17, 2020, 12 pages. |
| International Search Report and Written Opinion, PCT/US2023/065015, dated Jul. 17, 2023, 10 pages. |
| International Search Report and Written Opinion, PCT/US2023/065018, dated Jul. 7, 2023, 8 pages. |
| International Search Report and Written Opinion, PCT/US2023/065022, dated Jul. 26, 2023, 8 pages. |
| International Search Report and Written Opinion, PCT/US2023/065048, dated Jul. 14, 2023, 11 pages. |
| International Search Report and Written Opinion, PCT/US2023/065050, dated Jul. 7, 2023, 10 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20230312770 A1 | Oct 2023 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63326389 | Apr 2022 | US |
